---
title: "editorials insomnia"
year: 2024
month: 02
journal: "American Family Physician"
volume: "109-110"
issue: "02"
pages: ""
doi: ""
pmid: ""
source: "PDF Extraction"
pdf_available: true
original_pdf: "2024-02-editorials-insomnia.pdf"
extracted_date: "2025-08-10"
keywords: []
evidence_level: ""
clinical_significance: ""
---

# editorials insomnia

                                                                Editorials
        Insomnia:​Advancements and Limitations
           of Current Management Strategies
                       William J. Healy, MD, Medical College of Georgia at Augusta University, Augusta, Georgia
                               Rami N. Khayat, MD, University of California–Irvine, Irvine, California
                              Younghoon Kwon, MD, University of Washington, Seattle, Washington

            See related article on page 154.
                                                                                    Given the limitations in access to CBT-I, it is
            The relevance of the optimal management of                           critical for physicians to become familiar with its
            insomnia will not be lost on the practicing pri-                     five domains (cognitive restructuring, stimulus
            mary care physician, given that up to 50% of adults                  control, sleep hygiene, relaxation therapy, and
            report symptoms of acute or chronic insomnia.1,2                     sleep restriction). Particularly, sleep restriction
            Clinically, patients with insomnia have depressed                    and stimulus control should be emphasized. Sleep
            mood, poor school and work performance, and                          restriction improves sleep efficiency, or how much
            self-reported reduced quality of life.3,4 They also                  time in bed is spent sleeping. Stimulus control is a
            have an increased risk of cardiovascular diseases.5                  set of measures that emphasizes the use of the bed
            Economically, the condition generates direct and                     for sleep and reduces associations with it being a
            indirect costs of up to $100 billion each year.2,6                   cue for wakefulness. Ideally, physicians provid-
               An article in this issue of American Family Phy-                  ing behavioral interventions such as CBT-I in
            sician discusses the management of chronic insom-                    the office should seek additional training in this
            nia,7 and we applaud the authors for their practical                 domain and establish relationships with local and
            approach that emphasizes nonpharmacologic ther-                      regional CBT-I providers.14-16 Exercise improves
            apies. Primum non nocere (“first, do no harm”) is a                  sleep duration and quality and should also be dis-
            chief consideration in insomnia management. The                      cussed with patients.17
            longitudinal care provided by the family physician                      Guidelines on pharmacotherapy for insomnia
            is a strategic advantage in management because the                   are based on the best evidence available, which
            first step is a comprehensive assessment of medical                  is typically rated as weak by the GRADE system
            history, medications, use of substances, sleep his-                  due to methodologic issues related to conflicts of
            tory, and sleep-related symptoms.8                                   interest and variable outcomes that are difficult to
               The preferred first-line treatment for insomnia                   pool.8 When medications are required, physicians
            remains cognitive behavior therapy for insom-                        should limit pharmacotherapy to drugs labeled
            nia (CBT-I).9 Overall, the supporting evidence                       by the U.S. Food and Drug Administration for
            for treatment of chronic insomnia with CBT-I is                      insomnia and at approved dosages. Although the
            stronger than that for pharmacologic therapy.8                       overall rate of sleep aid prescriptions is decreas-
            One caveat is that certain patients, such as those                   ing, the variety of available agents is increasing.8
            with suicidal ideation and comorbid insomnia                            Notably, the effectiveness and safety of
            or other extreme circumstances, may require                          approved medications were tested in short-term
            judicious medical treatment up front to rapidly                      placebo-controlled randomized trials involving
            relieve symptoms.10                                                  adults with chronic insomnia (defined by sleep
               In-person CBT-I delivered by a psychologist is                    disturbances and associated daytime symptoms
            preferred. However, reimbursement and access                         three or more times each week for three or more
            issues have necessitated alternatives, including                     months despite adequate opportunity and cir-
            online modules, telemedicine, and self-directed                      cumstances for sleep). The long-term effectiveness
            therapy. Smartphone apps for insomnia behav-                         of these drugs has not been well established.
            ioral interventions are rapidly proliferating, but                      Use of benzodiazepines for chronic insomnia
            interfaces vary, and the apps are often poorly                       should be avoided in favor of newer pharmaco-
            studied.11,12 Perhaps the best-validated and most                    logic options that show less potential for harm.8
            used app is CBT-i Coach from the U.S. Depart-                        The Beers Criteria recommend caution with
            ment of Veterans Affairs.11,13                                       both benzodiazepines and nonbenzodiazepine

 Downloaded
February    from
         2024    the American
               ◆ Volume 109, Family
                              NumberPhysician
                                       2      website at www.aafp.org/afp.        © 2024 American Academy of Family
                                                                           Copyright
                                                            www.aafp.org/afp                                  American    Family
                                                                                                                     Physicians.     the private, 107
                                                                                                                                 ForPhysician     non-
commercial use of one individual user of the website. All other rights reserved. Contact copyrights@aafp.org for copyright questions and/or permission requests.
                                                                   EDITORIALS


          receptor agonists in patients older than 65 years.6,18                4. Edinger JD, Buysse DJ, Deriy L, et al. Quality measures for
                                                                                   the care of patients with insomnia. J Clin Sleep Med. 2015;​
          There is an emerging role for dual orexin recep-                         11(3):​311-334.
          tor antagonists in the management of insomnia;​                       5. Wu TT, Zou YL, Xu KD, et al. Insomnia and multiple health
          a recent network meta-analysis showed a favor-                           outcomes:​umbrella review of meta-analyses of prospec-
                                                                                   tive cohort studies. Public Health. 2023;​215:​66-74.
          able outcome in sleep parameters as well as safety
                                                                               6. Taddei-Allen P. Economic burden and managed care con-
          and tolerability.19 This development is exciting,                       siderations for the treatment of insomnia. Am J Manag
          although it remains unclear whether this class of                       Care. 2020;​26(4 suppl):​S91-S96.
          drugs will have better outcomes than previously                       7. Matheson EM, Brown BD, DeCastro AO. Treatment of
          approved medications, such as nonbenzodiaze-                             chronic insomnia in adults. Am Fam Physician. 2024;​
                                                                                   109(2):​154-160.
          pine receptor agonists.                                              8. Sateia MJ, Buysse DJ, Krystal AD, et al. Clinical practice
             Consensus is lacking on when to use over-the-                        guideline for the pharmacologic treatment of chronic
          counter sleep aids. Guidelines do not recommend                         insomnia in adults:​an American Academy of Sleep Med-
                                                                                  icine clinical practice guideline. J Clin Sleep Med. 2017;​
          routine use of diphenhydramine, melatonin,                              13(2):​307-349.
          L-tryptophan, or valerian for sleep onset or main-                    9. Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guide-
          tenance.8 When melatonin is used, it is best for                         line for the evaluation and management of chronic insom-
          adjusting circadian rhythm rather than directly                          nia in adults. J Clin Sleep Med. 2008;​4(5):​487-504.

          inducing sleep. Recent studies emphasize the                         10. McCall WV. Targeting insomnia symptoms as a path to
                                                                                   reduction of suicide risk:​the role of cognitive behavioral
          variability of endogenous melatonin levels among                         therapy for insomnia (CBT-I). Sleep. 2022;​45(12):​zsac260.
          patients and the variability of melatonin quantity                   11. Kaitz J, Robinson SA, Petrakis BA, et al. Veteran accep-
          in each supplement despite labeled amounts.20                            tance of sleep health information technology:​a mixed-
                                                                                   method study. J Technol Behav Sci. 2023;​8(1):​57-68.
             Optimizing the management of other comor-
                                                                               12. Aji M, Gordon C, Stratton E, et al. Framework for the
          bid chronic medical illnesses that contribute to                         design engineering and clinical implementation and eval-
          insomnia, such as asthma, chronic obstructive                            uation of mHealth Apps for sleep disturbance:​systematic
          pulmonary disease, heart failure, depression, and                        review. J Med Internet Res. 2021;​23(2):​e24607.

          anxiety, is required in addition to behavioral and                   13. U.S. Department of Veterans Affairs. Mental health and
                                                                                   behavioral therapy apps. Accessed October 30, 2023.
          pharmacologic therapies. There is much hope for                          https://​ m obile.va.gov/mental- ​ h ealth-​a nd-behavioral-
          patients with chronic insomnia given the expand-                         therapy-apps
          ing pipeline of medications and access to CBT-I.                     14. Taylor DJ, Pruiksma KE, Dietch JR, et al. CBTiweb.
                                                                                   Accessed October 1, 2023. https://​cbtiweb.org
          Family physicians are well positioned to make
                                                                               15. University of Pennsylvania Perelman School of Medicine.
          strides in improving this condition.                                     Training in cognitive behavioral therapy for insomnia
                                                                                   (CBT-I). Accessed October 1, 2023. https://​w ww.med.
          Address correspondence to William J. Healy, MD, at
                                                                                   upenn.edu/cbti/
          WIHEALY@​augusta.edu. Reprints are not available
                                                                               16. University of Pennsylvania Perelman School of Medicine.
          from the authors.
                                                                                   The international directory of CBT-I providers. Accessed
                                                                                   October 30, 2023. https://​cbti.directory
          Author disclosure:​No relevant financial
                                                                               17. Dolezal BA, Neufeld EV, Boland DM, et al. Interrelationship
          relationships.
                                                                                   between sleep and exercise:​a systematic review. Adv Prev
                                                                                   Med. March 26, 2017. Accessed November 7, 2023. https://​
          References                                                               www.ncbi.nlm.nih.gov/pmc/articles/PMC5385214/
           1. Perlis ML, Posner D, Riemann D, et al. Insomnia. Lancet.         18. American Geriatrics Society 2023 updated AGS Beers
              2022;​400(10357):​1047-1060.                                         Criteria® for potentially inappropriate medication use in
          2. Kessler RC, Berglund PA, Coulouvrat C, et al. Insomnia and            older adults. J Am Geriatr Soc. 2023;​71(7):​2052-2081.
             the performance of U.S. workers:​results from the America         19. Yue JL, Chang XW, Zheng JW, et al. Efficacy and tolerabil-
             insomnia survey [published corrections appear in Sleep.               ity of pharmacological treatments for insomnia in adults:​
             2012;​35(6):​725 and Sleep. 2011;​3 4(11):​1608]. Sleep. 2011;​       a systematic review and network meta-analysis. Sleep
             34(9):​1 161-1171.                                                    Med Rev. 2023;​68:​101746.
          3. Zammit GK, Weiner J, Damato N, et al. Quality of life in          20. Goldstein CA, Burgess HJ. Hit or miss:​the use of mela-
             people with insomnia. Sleep. 1999;​22(suppl 2):​S379-S385.            tonin supplements. J Clin Sleep Med. 2020;​16(S1):​29-30. ■




108 American Family Physician                                 www.aafp.org/afp                                 Volume 109, Number 2 ◆ February 2024
